EchoSolv HF FDA application receives NSE determination — Echo IQ outlines path forward
The US Food and Drug Administration (FDA) has issued a Not Substantially Equivalent (NSE) determination on Echo IQ’s initial EchoSolv HF 510(k) application, meaning the product has not received clearance for commercial use at this time. The company’s FDA-cleared EchoSolv AS platform remains unaffected, cash at bank exceeded $105 million as at July 2026, and US commercial momentum continues across the broader business.
This is a setback on one application, not a closure of the regulatory pathway or a disruption to the wider business. Echo IQ has already commenced a detailed review with its US regulatory and legal advisors, and management has outlined a clear set of near-term priorities to advance EchoSolv HF towards clearance.
Investors can register for a webinar at 8:30am AEST on Wednesday, 9 September, where CEO Dustin Haines, President of the US Nick Lubbers, and CFO Matthew Dodds will present and take questions. Registration is available at https://us02web.zoom.us/webinar/register/WN_LUL1CqldRaStHFNVul5Kig#/registration.
When big ASX news breaks, our subscribers know first
Understanding the FDA’s NSE determination
What does “Not Substantially Equivalent” mean under the 510(k) pathway?
The FDA’s 510(k) clearance process requires a company to demonstrate that its medical device is “substantially equivalent” to an existing legally marketed predicate device in terms of intended use and technological characteristics. If the FDA is not satisfied that this standard has been met, it issues an NSE determination.
An NSE determination is not a clinical rejection and does not constitute a finding that the device is unsafe. It means the initial submission did not satisfy the equivalence standard as assessed by the FDA. Importantly, it is not the end of the regulatory road.
Under FDA rules, companies that receive an NSE determination have several administrative and regulatory options available to them, including:
- Direct engagement with the FDA to clarify the matters raised in the determination
The investor takeaway is that the 510(k) pathway to clearance remains open. The NSE determination provides detailed feedback that now informs the company’s next submission strategy.
Echo IQ’s response strategy and business foundations intact
Regulatory and legal review underway
Echo IQ has commenced a detailed review of the regulatory matters raised in the NSE determination alongside its US regulatory and legal advisors, study partners, and independent statistical experts. The company has stated it “believes there is a pathway forward for clearance under the 510(k) route” and intends to engage directly with the FDA to clarify the matters identified. This process is intended to inform the most appropriate and efficient pathway to progress EchoSolv HF towards US regulatory clearance.
The company also noted that its view differs on certain aspects of the determination, though the NSE provides detailed feedback that can now be assessed and discussed directly with the FDA.
EchoSolv AS commercialisation unaffected
The NSE determination has no impact on the FDA-cleared EchoSolv AS platform or its ongoing commercialisation in the United States. Echo IQ confirmed it will continue to advance its US commercial infrastructure, reimbursement pathway, customer pipeline, and strategic relationships. These foundations are also expected to provide the platform to support future EchoSolv HF commercialisation, subject to obtaining the required regulatory clearance.
The company’s broader research and development pipeline, targeting additional disease states and new clinical modalities, also remains active.
Financial position provides strategic flexibility
Echo IQ held cash at bank of over $105 million as at July 2026, providing the runway and resources to pursue the additional regulatory work required. Management explicitly cited the strength of the balance sheet as a central foundation for the path forward.
Dustin Haines, CEO, Echo IQ
“Echo IQ is approaching this next phase from a position of strength. We have an FDA-cleared product in EchoSolv AS, a growing US presence, important strategic relationships and a strong balance sheet. These foundations remain unchanged and provide us with the resources and infrastructure required to progress the additional work necessary to advance EchoSolv HF towards regulatory clearance.”
What investors should watch next
The company’s near-term priorities, as outlined in the announcement, are as follows:
- Detailed review of the FDA’s NSE determination with US regulatory, legal, and independent statistical advisors
- Direct engagement with the FDA to clarify the matters identified in the determination
- Assessment of all administrative and regulatory options to determine the most appropriate and efficient clearance pathway
- Continued advancement of the FDA-cleared EchoSolv AS US commercialisation program
- Investor webinar at 8:30am AEST, Wednesday 9 September (CEO, US President, and CFO presenting with Q&A)
Echo IQ has stated it remains confident in the clinical rationale underpinning EchoSolv HF and the significant unmet clinical need in the identification of patients with heart failure. No specific timeline for re-submission or clearance has been disclosed.
| Item | Detail | Status | Investor Note |
|---|---|---|---|
| EchoSolv HF 510(k) | Initial application received NSE determination from the FDA | Not cleared for commercial use at this time | 510(k) pathway remains open; review and FDA engagement underway |
| EchoSolv AS | FDA-cleared AI platform | Unaffected; US commercialisation continues | Ongoing commercial and reimbursement activity in the US |
| Cash position | Over $105 million at bank as at July 2026 | Strong balance sheet maintained | Provides resources to fund additional regulatory work |
| Next regulatory step | Detailed review with US regulatory, legal, and statistical advisors; direct FDA engagement | In progress | No specific re-submission timeline disclosed |
| Investor webinar | CEO, US President, and CFO presenting with Q&A | 8:30am AEST, Wednesday 9 September | Registration via Zoom link provided in the announcement |
Stay Ahead on ASX Healthcare News
Join 20,000+ investors receiving FREE breaking ASX healthcare alerts delivered to their inbox within minutes of release, complete with in-depth analysis already done. When market-moving news breaks, being first matters. Click the “Free Alerts” button at Big News Blast to start receiving real-time coverage the moment announcements hit.